FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308545166> ?p ?o ?g. }

• W4308545166 abstract "<h3>Background</h3> Eftilagimod alpha (E) is a soluble LAG-3 protein binding to a subset of MHC class II molecules to mediate antigen-presenting cell (APC) activation & T-cell (CD4/CD8) recruitment/activation. By stimulating APCs with E, T cells are recruited, possibly leading to stronger anti-tumor responses than with pembrolizumab (P) alone, especially in tumors not overexpressing PD-L1. Herein we report results of the 1^st line non-small cell lung carcinoma (NSCLC) cohort in the TACTI-002 (“Two ACTive Immunotherapies”) trial. <h3>Methods</h3> Pts with measurable, 1^st line metastatic NSCLC unselected for PD-L1 were recruited. The objective response rate (ORR) by iRECIST was the primary endpoint (EP). Secondary EPs include ORR by RECIST 1.1, ORR by blinded independent central read (BICR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), PD-L1 and IFN-gamma, safety & tolerability. Pts received 30mg E SC q2w for 8 cycles (1 cycle= 3 weeks) & then q3w for up to 1 year with P (200 mg IV q3w for up to 2 years). Imaging was done every 8 weeks & assessed by investigator. PD-L1 was assessed centrally (22C3 antibody). The study was powered to detect a 52% increase in ORR compared to historical results for P 80% power & 1-sided alpha of 2.5%. Planned recruitment=110 pts. <h3>Results</h3> From Mar 2019-Nov 2021, 114 pts were enrolled. Median follow-up was 13 mo (data cut-off Jul 1^st 2022). Median age was 67 yrs (44-85) & 74% were male. ECOG PS was 0 & 1 in 37% & 63% of pts. Pts presented with squamous (35%) or non-squamous (63%) carcinoma and 93% had metastatic disease. All PD-L1 subgroups were represented (table 1). Pts received median 9.0 (range 1–18) P & 13.0 (1-22) E. 11 (9.6%) pts discontinued due to related adverse events (AEs). Common (≥15%) AEs were dyspnea (35%), asthenia (33%), decreased appetite (25%), cough (25%), anemia (23%), fatigue (21%), pruritus (21%), constipation (18%), nausea (17%), hemoptysis (16%) & diarrhea (16%). ORR by iRECIST (primary EP) was 39.5% (95% CI 30.5-49.1) & median PFS was 6.9 mo (95% CI 4.9-9.3). Responses were observed in all PD-L1 subgroups (table 1). ORR (iRECIST) for squamous & non-squamous were 37.5% & 38.9%. Median duration of response was 21.6 mo. Results acc. to RECIST 1.1 were comparable. Early & sustained increases of circulating CXCL-10 & IFN-gamma levels were observed. <h3>Conclusions</h3> E + P is safe & shows encouraging antitumor activity in 1^st line metastatic NSCLC patients unselected for PD-L1, warranting late-stage clinical investigation. <h3>Acknowledgements</h3> We thank all the participating patients & their families. We thank the dedicated clinical trial investigators & their team members. Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA provided pembrolizumab for the study. Sponsored by Immutep. <h3>Trial Registration</h3> The trial identifiers are TACTI-002 (sponsor code), IMP321-P015 (Sponsor code), Keynote-PN798 (MSD code), 2018-001994-25 (EudraCT) and NCT03625323 (ClinicalTrials.gov). <h3>Ethics Approval</h3> This has been approved by relevant Competent Authorities, Ethics Committees, and Institutional Review Boards." @default.
• W4308545166 created "2022-11-12" @default.
• W4308545166 creator A5003518821 @default.
• W4308545166 creator A5009341892 @default.
• W4308545166 creator A5012063249 @default.
• W4308545166 creator A5012670634 @default.
• W4308545166 creator A5013226213 @default.
• W4308545166 creator A5018378822 @default.
• W4308545166 creator A5019547742 @default.
• W4308545166 creator A5020985643 @default.
• W4308545166 creator A5029689781 @default.
• W4308545166 creator A5031237725 @default.
• W4308545166 creator A5042977767 @default.
• W4308545166 creator A5059355812 @default.
• W4308545166 creator A5062748174 @default.
• W4308545166 creator A5065988752 @default.
• W4308545166 creator A5073907665 @default.
• W4308545166 creator A5075473235 @default.
• W4308545166 creator A5080195917 @default.
• W4308545166 creator A5080991347 @default.
• W4308545166 creator A5090324173 @default.
• W4308545166 creator A5091281351 @default.
• W4308545166 date "2022-11-01" @default.
• W4308545166 modified "2023-10-03" @default.
• W4308545166 title "1470 Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: efficacy results from the 1st line non-small cell lung cancer cohort of TACTI-002 (Phase II)" @default.
• W4308545166 doi "https://doi.org/10.1136/jitc-2022-sitc2022.1470" @default.
• W4308545166 hasPublicationYear "2022" @default.
• W4308545166 type Work @default.
• W4308545166 citedByCount "0" @default.
• W4308545166 crossrefType "proceedings-article" @default.
• W4308545166 hasAuthorship W4308545166A5003518821 @default.
• W4308545166 hasAuthorship W4308545166A5009341892 @default.
• W4308545166 hasAuthorship W4308545166A5012063249 @default.
• W4308545166 hasAuthorship W4308545166A5012670634 @default.
• W4308545166 hasAuthorship W4308545166A5013226213 @default.
• W4308545166 hasAuthorship W4308545166A5018378822 @default.
• W4308545166 hasAuthorship W4308545166A5019547742 @default.
• W4308545166 hasAuthorship W4308545166A5020985643 @default.
• W4308545166 hasAuthorship W4308545166A5029689781 @default.
• W4308545166 hasAuthorship W4308545166A5031237725 @default.
• W4308545166 hasAuthorship W4308545166A5042977767 @default.
• W4308545166 hasAuthorship W4308545166A5059355812 @default.
• W4308545166 hasAuthorship W4308545166A5062748174 @default.
• W4308545166 hasAuthorship W4308545166A5065988752 @default.
• W4308545166 hasAuthorship W4308545166A5073907665 @default.
• W4308545166 hasAuthorship W4308545166A5075473235 @default.
• W4308545166 hasAuthorship W4308545166A5080195917 @default.
• W4308545166 hasAuthorship W4308545166A5080991347 @default.
• W4308545166 hasAuthorship W4308545166A5090324173 @default.
• W4308545166 hasAuthorship W4308545166A5091281351 @default.
• W4308545166 hasBestOaLocation W43085451661 @default.
• W4308545166 hasConcept C121608353 @default.
• W4308545166 hasConcept C126322002 @default.
• W4308545166 hasConcept C143998085 @default.
• W4308545166 hasConcept C147483822 @default.
• W4308545166 hasConcept C167672396 @default.
• W4308545166 hasConcept C197934379 @default.
• W4308545166 hasConcept C203014093 @default.
• W4308545166 hasConcept C203092338 @default.
• W4308545166 hasConcept C2776090121 @default.
• W4308545166 hasConcept C2776256026 @default.
• W4308545166 hasConcept C2776694085 @default.
• W4308545166 hasConcept C2777701055 @default.
• W4308545166 hasConcept C2778375690 @default.
• W4308545166 hasConcept C2780057760 @default.
• W4308545166 hasConcept C2780739268 @default.
• W4308545166 hasConcept C535046627 @default.
• W4308545166 hasConcept C71924100 @default.
• W4308545166 hasConcept C8891405 @default.
• W4308545166 hasConceptScore W4308545166C121608353 @default.
• W4308545166 hasConceptScore W4308545166C126322002 @default.
• W4308545166 hasConceptScore W4308545166C143998085 @default.
• W4308545166 hasConceptScore W4308545166C147483822 @default.
• W4308545166 hasConceptScore W4308545166C167672396 @default.
• W4308545166 hasConceptScore W4308545166C197934379 @default.
• W4308545166 hasConceptScore W4308545166C203014093 @default.
• W4308545166 hasConceptScore W4308545166C203092338 @default.
• W4308545166 hasConceptScore W4308545166C2776090121 @default.
• W4308545166 hasConceptScore W4308545166C2776256026 @default.
• W4308545166 hasConceptScore W4308545166C2776694085 @default.
• W4308545166 hasConceptScore W4308545166C2777701055 @default.
• W4308545166 hasConceptScore W4308545166C2778375690 @default.
• W4308545166 hasConceptScore W4308545166C2780057760 @default.
• W4308545166 hasConceptScore W4308545166C2780739268 @default.
• W4308545166 hasConceptScore W4308545166C535046627 @default.
• W4308545166 hasConceptScore W4308545166C71924100 @default.
• W4308545166 hasConceptScore W4308545166C8891405 @default.
• W4308545166 hasLocation W43085451661 @default.
• W4308545166 hasOpenAccess W4308545166 @default.
• W4308545166 hasPrimaryLocation W43085451661 @default.
• W4308545166 hasRelatedWork W2786497694 @default.
• W4308545166 hasRelatedWork W2898071776 @default.
• W4308545166 hasRelatedWork W2902679640 @default.
• W4308545166 hasRelatedWork W2987628800 @default.
• W4308545166 hasRelatedWork W3094659495 @default.
• W4308545166 hasRelatedWork W3100080748 @default.
• W4308545166 hasRelatedWork W3175277114 @default.
• W4308545166 hasRelatedWork W3215044659 @default.
• W4308545166 hasRelatedWork W4229043315 @default.
• W4308545166 hasRelatedWork W4304690509 @default.

• next